

Article

## Palladium-Catalyzed Regioselective C-H Alkenylation of Arylacetamides via Distal Weakly Coordinating Primary Amide as Directing Group

Yogesh Jaiswal, Yogesh Kumar, and Amit Kumar

*J. Org. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b02618 • Publication Date (Web): 25 Dec 2017

Downloaded from <http://pubs.acs.org> on December 25, 2017

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.


# Palladium-Catalyzed Regioselective C-H Alkenylation of Arylacetamides *via* Distal Weakly Coordinating Primary Amide as Directing Group

Yogesh Jaiswal, Yogesh Kumar and Amit Kumar\*

Department of Chemistry, Indian Institute of Technology Patna, Bihta 801106, Bihar, India

\*E-mail: [amitkt@iitp.ac.in](mailto:amitkt@iitp.ac.in) or [amitktiitk@gmail.com](mailto:amitktiitk@gmail.com)

## Graphical Abstract




## Abstract

Herein, we disclose the Pd(II)-catalyzed efficient and *regio*-selective *ortho* C-H alkenylation of arylacetamide derivatives *viz* weakly coordinating aliphatic primary amide. This protocol utilizes ubiquitous free primary amide as the directing group and circumventing two troublesome steps of installation and removal of an external auxiliary. This strategy directly enables the incorporation of a synthetically versatile olefin in the products in moderate to good yields with *regio* and distereo-selective fashion. The alkenylated acetamides can be easily manipulated and further transformed into a variety of useful derivatives.

## Introduction




Amide bonds are the key structural unit that is present in many physiologically active compounds (Figure 1) beside their ubiquitous presence in biopolymers, for instance, proteins and

glycoproteins.<sup>1</sup> The amide functionality also serves as an important building block in organic synthesis and in recent year extensively utilized as a directing group for direct C-H bond activation *viz* cyclopalladation.<sup>2</sup> In this context, pioneer work has been done by Yu, Miura, Daugulis, Glorius, Ackermann, and Dong *et al.* where *N*-substituted secondary<sup>3</sup> and tertiary amides<sup>4</sup> have been used as a directing group for *chemo* and *regio*-selective C-H bond functionalization. In spite of these significant progresses, free form of amide, in particularly, aliphatic primary amide group (-CH<sub>2</sub>CONH<sub>2</sub>) has been rarely utilized as directing group for C-H bond transformation.<sup>5</sup> Moreover, the primary amide group is more venerable for further functional group inter-conversion after the desired installation. Therefore, an important challenge in the area of direct C-H bond functionalization is to find out a simple and ubiquitous functional group, which can be used as directing group for distal C-H bond activation reaction, without the need of pre-installation, which eventually increases the atom and step economy.



**Figure 1:** Biologically active molecules containing phenylacetamide motif.


1  
2  
3 Carbon-carbon bond formation *viz* transition metal catalyzed two-fold C-H activation (Fujiwara-  
4 Moritani reaction), in particular, the directing group assisted  $\sigma$ -chelation control reactions have  
5 emerged as economical and handful tools in organic synthesis.<sup>6</sup> A range of the directing groups  
6 has been introduced on aryl motifs, which control the *regio*-selectivity. However, a major  
7 limitation of these strategies lies in requirements of pre-installation of directing groups followed  
8 by their uninstallation after the desired operation.<sup>7</sup> Recently Yu *et al.*<sup>8a</sup> (Scheme 1a) and Maity  
9 and coworkers<sup>8b</sup> (Scheme 1b) elegantly demonstrated the application of *N*-substituted secondary  
10 and tertiary acetamide as an effective distal directing group for *ortho*-C-H olefination of  
11 phenylacetamide derivatives. While these  $\sigma$ -chelation-assisted reactions were quite effective for  
12 C-C bond formation, Pd-catalyzed oxidative alkenylation with the prevalent functional group,  
13 such as aliphatic primary acetamide as a weak coordinating group has never been reported.  
14 Recently, our group introduced the use of aliphatic primary acetamide as a versatile directing  
15 group for *regio*-selective *ortho*-C-H arylation of phenylacetamides derivatives.<sup>9</sup> Substantial  
16 advantage of this distal and weakly coordinating directing group is due to the presence of free  
17 amide moiety, which can be easily manipulated by the different functional groups. In our  
18 continued efforts to synthesize multifunctionalized arenes,<sup>10</sup> herein we disclose, an efficient  
19 Pd(II)-catalyzed mono-*ortho*-olefination of phenylacetamides derivatives *via* distal C-H bond  
20 activation (Scheme 1c). The generality of this protocol is demonstrated by preparing a  
21 commendable set of E-alkenylated compounds.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**(a) Quinoline based DG****(b) Weinreb Amide as DG****(c) Primary amide as DG (This work)****Scheme 1.** Weakly coordinating directing group assisted alkenylation of arylacetamides.**Result and Discussion**

Excited from our recent finding, we were further interested to explore the distal directing ability for two-fold C-H activation (Fujiwara-Moritani reaction) on arylacetamides without installing any additional auxiliary. However, to utilize the aliphatic primary amide as a directing group for distal C-H bond activation is by no means routine transformation and not comparable to primary benzamide as a directing group. The presence of free rotating methylene group ( $-CH_2$ ) between amide group and aryl ring of phenylacetamides increases the challenges in the manifold. Considering this fact, we commenced our studies by selecting phenylacetamide **1a** as model substrate and electron deficient ethyl acrylate **2a** as a coupling partner and palladium (II) salt as a choice of metal catalyst. Other reaction parameters such as solvent, oxidant and reaction temperature (for detailed information see Supporting Information) were optimized for *regio-*

selective *ortho*-alkenylation of phenylacetamides and results are tabulated in Table 1. To our delight, 43% of desired product **3a** was obtained using 10 mol% Pd(OAc)<sub>2</sub> in presence of Ag<sub>2</sub>CO<sub>3</sub> in AcOH solvent at 100 °C for 36 h (Table 1, entry1). Among a broad range of solvents surveyed TFA, AcOH, HIFA, ACN, DMF, and TFE, TFA provided the desired product in superior yield (Table 1, entry 6). Next, the effects of various oxidants were also investigated and it was found the efficiency of the desired transformation increased when benzoquinone (BQ) (entry 12) was used as oxidant under a molecular oxygen atmosphere. Interestingly, we observed that loading of benzoquinone (BQ) plays a significant effect on the efficiency of the overall process (see SI). For example, when the reaction was carried out with 1.0 equiv. of benzoquinone (BQ) under standard conditions, afforded the olefinated product **3a** in 72% yield (entry 13). The yield of the transformation was almost unaffected by increasing the reaction temperature (100 °C to 120 °C) and time (see SI). Similarly, the use of excess amount of ethyl acrylate (3.0 equiv.) does not affect the product yield considerably. It must be noted that throughout this optimization there was no evidence of *N*-alkenylated product formation, which was a primary concern as primary amide is vulnerable precursor to undergo intermolecular *N*-alkenylation.<sup>11</sup> Finally, the reaction conditions described in entry 13, Table-1 were selected as the standard reaction conditions for further exploration.

**Table 1. Optimization of Reaction Conditions<sup>a</sup>**



Entry	Solvent	Oxidant	Yield <sup>b</sup> (%)
1	AcOH	Ag <sub>2</sub> CO <sub>3</sub>	43


2	HFIP	Ag <sub>2</sub> CO <sub>3</sub>	36
3	TFE	Ag <sub>2</sub> CO <sub>3</sub>	40
4	ACN	Ag <sub>2</sub> CO <sub>3</sub>	12
5	DMF	Ag <sub>2</sub> CO <sub>3</sub>	18
6	TFA	Ag <sub>2</sub> CO <sub>3</sub>	50
7	TFA	Ag <sub>2</sub> O	45
8	TFA	CH <sub>3</sub> CO <sub>2</sub> Ag	50
9	TFA	AgBF <sub>4</sub>	0
10	TFA	CF <sub>3</sub> CO <sub>2</sub> Ag	53
11	TFA	AgNO <sub>3</sub>	40
12	TFA	BQ/O <sub>2</sub>	63
13	TFA	BQ/O <sub>2</sub>	72 <sup>c</sup>
14	TFA	Cu(OAc) <sub>2</sub> /O <sub>2</sub>	55

<sup>a</sup>Reaction conditions: **1a** (0.2 mmol), **2a** (0.6 mmol), Pd(OAc)<sub>2</sub> (10 mol%), oxidant (2.0 equiv.) solvent (2.0 mL), at 100 °C for 36 h. <sup>b</sup>Isolated yield after column chromatography. <sup>c</sup>Oxidant (1.0 equiv.). BQ = Benzoquinone

With these optimized reaction conditions in hand, we explored the reaction scope with a variety of substituted alkenes and results are summarized in Table 2. With the parent system **1** an array of acrylates were examined to furnish E-alkenylated products. For example, differentially substituted acrylic esters such as methyl to *n*-butyl all afforded the corresponding *ortho*-olefinated products (**3a-3d**) and yields were in the range of 56-72% with excellent *regio*-selectivity. Fortunately, when the reaction was carried out with other electron deficient alkenes, for instance, phenyl vinyl sulfone (**2e**), diethyl vinylphosphonate (**2f**) and phenoxyethyl acrylate (**2g**) as a coupling partner, desired products (**3e-3g**) were isolated in good to moderate yields (70%-32%). However, we observed that when the reactions were carried out with unactivated alkenes such as styrene (**2h**) and 4-fluoro styrene (**2i**) under optimized reaction conditions, the desired products were isolated in trace amount along with the formation of polymerized products and some starting material was also recovered. Surprisingly, by changing the solvent from

trifluoroacetic acid to acetic acid afforded the corresponding products (**3h** and **3i**) albeit in low yields 37% and 33% respectively.

**Table 2. Scope of Alkene Derivatives<sup>a</sup>**




<sup>a</sup>Reaction conditions: see entry 13, Table 1. <sup>b</sup>AcOH was used as a solvent.

Next, we extended the scope of the alkenylation reaction using a range of substituted arylacetamides with various alkenes (Table 3). Electron donating group such as methoxy, methyl and 3,4-dioxy at *meta* and *para* positions of aryl ring underwent smooth alkenylation reaction with activated acrylates to give *regio*-selective mono alkenylated products in good yields (53-62%, **4a-4d**). Furthermore, when moderate electron withdrawing group such as fluorine was introduced at *meta*-position of an aryl ring, desired product **4e** was procured in lower yield (34%). It is worth to mention that, *meta*-substituted substrates such as **1c**, **1d** and **1e** containing

two possible sites for C-H bond alkenylation proceeded selectively at the least sterically hindered position to afford **4c**, **4d** and **4e** as the sole products. When 4-methyl phenylacetamide was employed to couple with diethyl vinyl phosphonate desired olefinated product (**4f**) was obtained in moderate yield (42%). Reaction of phenyl vinyl sulfone with *para*-methyl and *para*-methoxy substituted arylacetamide underwent smooth conversion to give alkenylated products in good yield 68% and 65% respectively (**4g-4h**). Pleasingly, halogen substituted arylacetamide were also compatible with phenyl vinyl sulfone to give *ortho*-alkenylated products in acceptable yields (33%-38%, **4i** and **4j**), which could provide a handle for further synthetic elaboration. Delightfully, styrene was successfully coupled with *para*-methyl and methoxy substituted phenylacetamides (**4k** and **4l**).


**Table 3. Scope with regard to the arylacetamides and alkenes<sup>a</sup>**



<sup>a</sup>Reaction conditions: see entry 13, Table 1. <sup>b</sup>AcOH was used as a solvent.

Further, we became interested to check the scope of  $\alpha$ -methyl phenylacetamide as directing group for *ortho*-olefination reaction under the optimized reaction conditions (Table 4). Interestingly, ethyl acrylate and phenyl vinyl sulfone reacted well to afford the corresponding *mono*-olefinated products in good yields (61-64%, **6a** and **6b**). Similarly, other alkenes such as diethyl vinylphosphonate and styrene were also coupled to give the corresponding products in moderate yields (42-45%, **6c** and **6d**).


**Table 4. Scope of olefins with  $\alpha$ -methyl phenylacetamide<sup>a</sup>**



<sup>a</sup>Reaction conditions: see entry 13, Table 1. <sup>b</sup>AcOH was used as a solvent.


To demonstrate the synthetic utility, we performed scale-up experiment with 4.0 mmole of phenylacetamide **1a** with ethyl acrylate **2a** under standard conditions. The olefinated product **3a** was isolated in 57% yield and there was a slight drop in the yield in scale-up reaction (Scheme 2).

---

**Scheme 2. Preparative Scale Experiment**


After this primary acetamide directed *ortho*-alkenylation strategy was established, the further synthetic transformation of alkenylated phenylacetamide product **3a** was explored. Amide group can be easily manipulated to different functional groups as per requirements under given conditions. Treatment of **3a** with a catalytic amount of  $\text{PdCl}_2$  in the mixture of  $\text{CH}_3\text{CN}$  and water led to dehydration to afford **7a** in 82% yield without affecting ester group. Similarly, when **3a** was treated with iodobenzene and oxone in presence of methanol, amide group was converted to ester via *trans* esterification to give **7b** in 70% yield. Furthermore, the functionalizable primary amide and ester groups can be easily hydrolyzed to the corresponding dicarboxylic acid **7c** by treating with 20%  $\text{H}_2\text{SO}_4$  at  $100\text{ }^\circ\text{C}$  for 6h (Scheme 3).


---

**Scheme 3. Functional Group Transformation of 3a**



1  
2  
3 In order to obtain desired information about the electronic preference of reaction, the  
4 intermolecular competition experiments were performed. When an equimolar amount of *meta*  
5 substituted electron rich **1d** and electron deficient **1e** were allowed to compete under standard  
6 conditions in coupling with ethyl acrylate, result highlighted that electron donating **1d** shows  
7 higher reactivity with conversion ratio 3.6:1 over **1e** (Scheme 4a, eq. 1). Similarly, when  
8 phenylacetamide **1a** reacted with an equimolar amount of ethyl acrylate and phenyl vinyl sulfone  
9 under standard conditions, approximately equal amount of product was isolated (1:1) (Scheme  
10 4a, eq. 2). This result demonstrates that both types of alkene have similar reactivity toward the  
11 acetamide derivatives. Next, we performed a control experiment in the presence of radical  
12 scavenger 2,2,6,6-tetramethylpiperidine N-oxide (TEMPO) (Scheme 4b). There was no  
13 significant drop in yield of product formation, the observed results implied that the reaction is  
14 likely not to involve a single electron pathway. To gain further insight into the reaction  
15 mechanism, intermolecular isotope kinetic experiment was performed between **1a** and **1a-d<sub>5</sub>**. An  
16 isotope kinetic effect (KIE) of 4.0 was disclosed, thus suggesting that the palladium mediated C-  
17 H bond cleavage could potentially be involved in the rate-limiting step (RLS) in the catalytic  
18 cycle (Scheme 4c).<sup>12</sup> Notably, when *N*-substituted phenylacetamide **8** was subjected under  
19 optimal reaction conditions for *ortho*-alkenylation, the desired product **9** was obtained, albeit in  
20 low yield (25%, yield was not optimized at this stage with *N*-substituted phenylacetamides,  
21 Scheme 4d).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Scheme 4. Mechanistic Study


### (a) Intermolecular competition experiment




### (b) Radical trapping experiment



### (c) Competition experiment between 1a and 1a-d<sub>5</sub>




### d) Reaction with N-benzyl phenylacetamide



On the basis of earlier literature reports<sup>13</sup> and aforementioned results, we propose the plausible reaction mechanism for the *ortho*-alkenylation reaction *via* weakly coordinating directing group

(Scheme 5). The initial step is likely to be an *ortho* C–H bond activation directed by the carbonyl oxygen<sup>9, 14</sup> of phenylacetamide, thus affording six-membered cyclometalated intermediate **A** by the elimination of trifluoroacetic acid. Next, alkene coordinates and insert into Pd–C bond to form eight-membered palladacycle **C**. Finally,  $\beta$ -hydrogen elimination of **C** leads to the desired product and Pd(0) species, which is oxidized to Pd(II) by benzoquinone and completing the catalytic cycle.

### Scheme 5. Proposed Mechanism



In summary, we have demonstrated that aliphatic primary acetamides ( $-\text{CH}_2\text{CONH}_2$ ) are effective distal directing groups in transition metal catalyzed C–H activation. A variety of alkenyl groups have been remotely incorporated at *ortho*-positions of aryacetamide derivatives selectively *via* weakly coordinating primary amide as directing groups. Furthermore, this strategy avoids troublesome two extra steps of installation and removal of external directing

1  
2  
3 groups, which eventually decrease the overall cost in terms of time, waste and economy and  
4 evade the formation of *N*-alkenylated acetamide derivatives. We anticipate that wide availability  
5 of starting materials and high importance of primary aliphatic amides in the field of medicines,  
6 this developed strategy will find a broad applications in organic synthesis.  
7  
8  
9  
10  
11  
12

## 13 **EXPERIMENTAL SECTION**

### 14 **General Consideration:**

15  
16  
17  
18  
19 Unless otherwise noted, all reagents were purchased from a commercial supplier and used  
20 without further purification. All the starting material, aryl acetamides were prepared by  
21 following known literature procedure.<sup>15</sup> All the reactions were run under oxygen and indicated  
22 temperature was that of an oil bath. <sup>1</sup>H NMR spectra were recorded at 400 MHz and <sup>13</sup>C{<sup>1</sup>H}  
23 NMR spectra were recorded at 100 MHz, CDCl<sub>3</sub> and DMSO-*d*<sub>6</sub> were used as a solvent. Chemical  
24 shifts are reported in δ ppm referenced to CDCl<sub>3</sub> (δ 7.26), DMSO-*d*<sub>6</sub> (δ 2.50) for <sup>1</sup>H NMR and  
25 CDCl<sub>3</sub> (δ 77.0), DMSO-*d*<sub>6</sub> (δ 39.5) for <sup>13</sup>C NMR. The following abbreviations were used to  
26 explain multiplicities: (s, singlet; d, doublet; t, triplet; q, quartet; m, multiple, brs, broad singlet),  
27 coupling constant (Hertz). Infrared spectra were recorded by FT-IR apparatus. High-resolution  
28 mass spectra (HRMS) spectra were obtained on ESI-TOF (electron spray ionization-time of  
29 flight) spectrometer and methanol was used to dissolve the sample. Column chromatography was  
30 performed on silica gel (100-200) mesh using ethyl acetate and hexanes or ethyl acetate/DCM as  
31 eluent in different ratio.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **General procedure for olefination reaction (GP-A):** To a clean oven-dried 25 mL round bottom  
51 flask equipped with magnetic stir bar was sequentially added aryl acetamide (0.4 mmol),  
52 Pd(OAc)<sub>2</sub> (10 mol %, 8.9 mg), benzoquinone (0.4 mmol, 1.0 equiv, 43.2 mg). Then ethyl  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 acrylate (1.2 mmol, 3.0 equiv, 127.8  $\mu\text{L}$ ) followed by trifluoroacetic acid (4.0 mL) was added to  
4 the reaction mixture. The reaction mixture was purged with oxygen thrice. The flask was  
5 connected to oxygen ballon through condenser. The reaction mixture was placed in pre heated oil  
6 bath of 100  $^{\circ}\text{C}$  and vigorously stirred for 36 h. After completion, the reaction mixture was cooled  
7 to room temperature and solvent was evaporated under reduced pressure and diluted with ethyl  
8 acetate followed by neutralization with saturated solution of sodium bicarbonate. After extraction  
9 with ethyl acetate (15 mL x 3) organic layer was washed with brine solution and passed through  
10 short pad of celite and dried over sodium sulphate. After evaporation of solvent, the crude  
11 mixture was purified by column chromatography silica gel and ethyl acetate/hexanes or ethyl  
12 acetate/DCM as eluent.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26  
27 **(E)-Ethyl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (3a):** Following GP-A the title  
28 compound was isolated as white solid (67 mg, 72% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.35; Mp  
29 110-112  $^{\circ}\text{C}$ ; IR(ATR) 3389, 3188, 2927, 1711, 1659, 1626, 1398  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
30  $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.39-7.29 (m, 3H), 6.37 (d,  $J$  =  
31 16.0 Hz, 1H), 5.87 (brs, 1H), 5.61 (brs, 1H), 4.25 (q,  $J$  = 8.0 Hz, 2H), 3.72 (s, 2H), 1.32 (t,  $J$  =  
32 8.0 Hz, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.6, 166.6, 141.0, 134.2, 134.0, 131.4, 130.5,  
33 128.2, 127.2, 121.0, 60.7, 40.6, 14.3; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{13}\text{H}_{16}\text{NO}_3$   $[\text{M} + \text{H}]^+$   
34 234.1125, found 234.1141.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **(E)-Methyl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (3b):** Following GP-A the title  
47 compound was isolated as white solid (53 mg, 61% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3; Mp  
48 152-154  $^{\circ}\text{C}$ ; IR (ATR) 3392, 3181, 2923, 1705, 1658, 1393, 763  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
49  $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.38-7.29 (m, 3H), 7.38 (d,  $J$  =  
50 16.0 Hz, 1H), 5.88 (brs, 1H), 5.55 (brs, 1H), 3.79 (s, 3H), 3.72 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100  
51 152-154  $^{\circ}\text{C}$ ; IR (ATR) 3392, 3181, 2923, 1705, 1658, 1393, 763  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
52  $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.38-7.29 (m, 3H), 7.38 (d,  $J$  =  
53 16.0 Hz, 1H), 5.88 (brs, 1H), 5.55 (brs, 1H), 3.79 (s, 3H), 3.72 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100  
54 152-154  $^{\circ}\text{C}$ ; IR (ATR) 3392, 3181, 2923, 1705, 1658, 1393, 763  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
55  $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.38-7.29 (m, 3H), 7.38 (d,  $J$  =  
56 16.0 Hz, 1H), 5.88 (brs, 1H), 5.55 (brs, 1H), 3.79 (s, 3H), 3.72 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100  
57 152-154  $^{\circ}\text{C}$ ; IR (ATR) 3392, 3181, 2923, 1705, 1658, 1393, 763  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
58  $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.38-7.29 (m, 3H), 7.38 (d,  $J$  =  
59 16.0 Hz, 1H), 5.88 (brs, 1H), 5.55 (brs, 1H), 3.79 (s, 3H), 3.72 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100  
60 152-154  $^{\circ}\text{C}$ ; IR (ATR) 3392, 3181, 2923, 1705, 1658, 1393, 763  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  
 $\text{CDCl}_3$ )  $\delta$  7.91 (d,  $J$  = 16.0 Hz, 1H), 7.61 (d,  $J$  = 8.0 Hz, 1H), 7.38-7.29 (m, 3H), 7.38 (d,  $J$  =  
16.0 Hz, 1H), 5.88 (brs, 1H), 5.55 (brs, 1H), 3.79 (s, 3H), 3.72 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100

MHz, CDCl<sub>3</sub>)  $\delta$  172.6, 167.0, 141.3, 134.2, 134.0, 131.3, 130.5, 128.2, 127.2, 120.6, 51.8, 40.5;  
HRMS (ESI-TOF) *m/z* Calcd for C<sub>12</sub>H<sub>14</sub>NO<sub>3</sub> [M + H]<sup>+</sup> 220.0981, found 220.0968.

**(E)-Propyl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (3c):** Following **GP-A** the title compound was isolated as white solid (62 mg, 63% yield); R<sub>f</sub> (6:4 Hexanes/Acetone) = 0.35; Mp 111-113 °C; IR (ATR), 3351, 3185, 1701, 1654, 1631, 1408, 1183, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.92 (d, *J* = 16.0 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.38-7.30 (m, 3H), 6.40 (d, *J* = 16.0 Hz, 1H), 5.60 (brs, 1H), 5.45 (brs, 1H), 4.16 (t, *J* = 8.0 Hz, 2H), 3.73 (s, 2H), 1.75-1.70 (m, 2H), 0.99 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.6, 166.7, 141.0, 134.10, 134.08, 131.3, 130.5, 128.2, 127.2, 121.1, 66.3, 40.5, 22.0, 10.4; HRMS (ESI-TOF) *m/z* Calcd for C<sub>14</sub>H<sub>18</sub>NO<sub>3</sub> [M + H]<sup>+</sup> 248.1281, found 248.1294.

**(E)-Butyl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (3d):** Following **GP-A** the title compound was isolated as white solid (58 mg, 56 % yield); R<sub>f</sub> (6:4 Hexanes/Acetone) = 0.4; Mp 112-114 °C; IR (ATR) 3352, 3180, 1708, 1657, 1630, 1413, 1172, 765 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.91 (d, *J* = 16.0 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.40-7.29 (m, 3H), 6.39 (d, *J* = 16.0 Hz, 1H), 5.67 (brs, 1H), 5.54 (brs, 1H), 4.20 (t, *J* = 6.8 Hz, 1H), 3.73 (s, 2H), 1.72-1.65 (m, 2H), 1.47-1.38 (m, 2H), 0.96 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.4, 166.7, 140.9, 134.1, 131.3, 130.5, 128.2, 127.3, 121.2, 66.7, 40.5, 30.7, 19.2, 13.7; HRMS (ESI-TOF) *m/z* Calcd for C<sub>15</sub>H<sub>19</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup> 284.1275, found 284.1285.

**(E)-2-[2-(2-Benzenesulfonyl-vinyl)-phenyl]-acetamide (3e):** Following **GP-A** the title compound was isolated as brownish solid (76 mg, 70% yield); R<sub>f</sub> (6:4 Hexanes/EtOAc) = 0.25; Mp 147-149 °C; IR (ATR) 3395, 3207, 2924, 1711, 1623, 1306, 1142 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub> + CDCl<sub>3</sub>)  $\delta$  7.94-7.89 (m, 3H), 7.76-7.70 (m, 2H), 7.67-7.61 (m, 3H), 7.48 (d, *J* =

1  
2  
3 16.0 Hz), 7.38-7.26 (m, 3H), 3.64 (s, 2H);  $^{13}\text{C}$  NMR (400 MHz, DMSO +  $\text{CDCl}_3$ )  $\delta$  171.4,  
4  
5 140.7, 140.0, 136.6, 133.1, 131.6, 131.2, 130.5, 129.2, 128.3, 127.1, 127.0, 126.9, 39.4; HRMS  
6  
7 (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{16}\text{H}_{16}\text{NO}_3\text{S}[\text{M} + \text{H}]^+$  302.0845, found 302.0860.

8  
9  
10 **(E)-2-{2-[2-(Diethyl-phosphinoyl)-vinyl]-phenyl}-acetamide (3f):** Following **GP-A** the title  
11  
12 compound was isolated as brownish sticky solid (51 mg, 43 % yield);  $R_f$  (EtOAc) = 0.2;  
13  
14 IR(ATR) 3343, 3194, 2987, 1671, 1391, 1219, 1018, 958;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.76  
15  
16 (dd,  $J$  = 16.0 Hz, 8.0 Hz, 1H), 7.57 (d,  $J$  = 7.2 Hz, 1H), 7.36-7.33 (m, 3H), 6.26-6.16 (m, 2H),  
17  
18 5.81 (brs, 1H), 4.13-4.10 (m, 4H), 3.69 (s, 2H), 1.34 (t,  $J$  = 6.8 Hz, 6H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100  
19  
20 MHz,  $\text{CDCl}_3$ )  $\delta$  172.7, 145.8, 134.5 and 134.3 (d,  $J_{\text{C-P}}$  = 22.0 Hz), 134.1, 131.5, 130.5, 128.0,  
21  
22 126.7, 117.6 and 115.7 (d,  $J_{\text{C-P}}$  = 189.0 Hz), 62.13, 62.08, 40.2, 16.39, 16.33; HRMS (ESI-TOF)  
23  
24  $m/z$  Calcd for  $\text{C}_{14}\text{H}_{20}\text{NNaO}_4\text{P} [\text{M} + \text{Na}]^+$  320.1022, found 320.1029.

25  
26  
27 **(E)-2-Phenoxyethyl 3-(2-(2-amino-2-oxoethyl)phenyl)acrylate (3g):** Following **GP-A** the title  
28  
29 compound was isolated as white solid (43 mg, 32% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3; Mp  
30  
31 136-138  $^\circ\text{C}$ ; IR(ATR) 3395, 3199, 2925, 1712, 1651, 1395, 1217, 1045, 745  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400  
32  
33 MHz,  $\text{CDCl}_3$ )  $\delta$  7.96 (d,  $J$  = 16 Hz, 1H), 7.62 (d,  $J$  = 4.0 Hz, 1H), 7.41-7.23 (m, 5H), 7.0-6.93  
34  
35 (m, 3H), 6.44 (d,  $J$  = 16 Hz, 1H), 5.47 (brs, 1H), 5.39 (brs, 1H), 4.57 (t,  $J$  = 4.8 Hz, 2H), 4.25 (t,  
36  
37  $J$  = 4.8 Hz, 2H), 3.72 (s, 2H),  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.8, 166.5, 158.5, 141.8,  
38  
39 143.1, 133.9, 131.4, 130.7, 129.6, 128.3, 127.3, 121.2, 120.4, 114.7, 65.9, 63.1, 40.4; HRMS  
40  
41 (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{19}\text{H}_{19}\text{NNaO}_4 [\text{M} + \text{Na}]^+$  348.1206, found 348.1202.

42  
43  
44 **(E)-2-(2-styrylphenyl)acetamide (3h):** Following **GP-A** the title compound was isolated as  
45  
46 white solid (35 mg, 37% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.5; Mp 147-149  $^\circ\text{C}$ ; IR (ATR) 3397,  
47  
48 3205, 1657, 1404, 964, 762  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.79 (d,  $J$  = 8.0 Hz, 1H), 7.51  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(d,  $J = 8.0$  Hz, 2H), 7.38-7.26 (m, 7H), 7.04 (d,  $J = 16.0$  Hz, 1H), 5.53 (brs, 1H), 5.35 (brs, 1H), 3.74 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.4, 137.1, 137.0, 132.5, 131.9, 131.0, 128.8, 128.3, 128.2, 128.0, 126.8, 126.4, 124.9, 41.4; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{16}\text{H}_{15}\text{NaNO}$   $[\text{M} + \text{Na}]^+$  260.1046, found 260.1046.

**(E)-2-(2-(4-Fluorostyryl)phenyl)acetamide (3i):** Following **GP-A** the title compound was isolated as white solid (34 mg, 33% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3; Mp 161-163 °C; IR (ATR) 3386, 3194, 2921, 1653, 1505, 1398, 760  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.74 (d,  $J = 8.0$  Hz, 1H), 7.55 (t,  $J = 5.4$  Hz, 2H), 7.43-7.30 (m, 4H), 7.14-7.05 (m, 3H), 5.61 (brs, 1H), 5.44 (brs, 1H), 3.81 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.2, 163.83 and 161.37 (d,  $J_{\text{C-F}} = 246.0$  Hz), 137.0, 133.22 and 133.19 (d,  $J_{\text{C-F}} = 3.0$  Hz), 132.5, 131.1, 130.6, 128.36 and 128.31 (d,  $J_{\text{C-F}} = 5.0$  Hz), 128.3, 126.3, 124.8, 115.85 and 115.63 (d,  $J = 22.0$  Hz), 41.5; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{16}\text{H}_{15}\text{FNO}$   $[\text{M} + \text{H}]^+$  256.1132, found 256.1138.

**(E)-3-(2-Carbamoylmethyl-5-methoxy-phenyl)-acrylic acid methyl ester (4a):** Following **GP-A** the title compound was isolated as white solid (53 mg, 53% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.25; Mp 153-155°C; IR (ATR) 3385, 3199, 2916, 1710, 1651, 1428, 1177  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.85 (d,  $J = 16.0$  Hz, 1H), 7.20 (d,  $J = 8.0$  Hz, 1H), 7.10 (s, 1H), 6.93 (d,  $J = 8.0$  Hz, 1H), 6.36 (d,  $J = 16.0$  Hz, 1H), 5.87 (brs, 1H), 5.53 (brs, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.65 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.6, 167.0, 159.3, 141.3, 135.0, 132.5, 126.2, 120.8, 116.5, 112.1, 55.4, 51.9, 39.5; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{13}\text{H}_{16}\text{NO}_4$   $[\text{M} + \text{H}]^+$  250.1074, found 250.1084.

**(E)-Ethyl 3-(2-(2-amino-2-oxoethyl)-5-methylphenyl)acrylate (4b):** Following **GP-A** the title compound was isolated as white solid (60 mg, 61% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3;

1  
2  
3 Mp130-132 °C; IR (ATR) 3377, 3187, 2922, 1712, 1655, 1404, 1177, 1040, 653 cm<sup>-1</sup>; <sup>1</sup>H NMR  
4 (400 MHz, CDCl<sub>3</sub>) δ 7.98 (d, *J* = 12.0 Hz, 1H), 7.53 (s, 1H), 7.29 (s, 2H), 6.48 (d, *J* = 12 Hz,  
5 1H), 6.06 (brs, 1H), 5.64 (brs, 1H), 4.35 (q, *J* = 7.2 Hz, 2H), 3.78 (s, 2H), 2.46 (s, 3H), 1.43 (t, *J*  
6 = 6.8 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 173.0, 166.7, 141.1, 137.9, 133.8, 131.33,  
7 131.26, 131.24, 129.7, 129.3, 127.7, 120.7, 60.6, 40.1, 21.0, 14.3; HRMS (ESI-TOF) *m/z* Calcd  
8 for C<sub>14</sub>H<sub>17</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup> 270.1101, found 270.1104.  
9  
10  
11  
12  
13  
14  
15  
16  
17

18 **(E)-3-(6-Carbamoylmethyl-benzo[1,3]dioxol-5-yl)-acrylic acid ethyl ester (4c):** Following  
19 **GP-A** the title compound was isolated as white solid (68 mg, 62% yield); R<sub>f</sub> ( 6:4  
20 Hexanes/EtOAc) = 0.3; Mp 167-169 °C; IR (ATR) 3391, 3190, 2921, 1693, 1655, 1448, 1255,  
21 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, *J* = 16.0 Hz, 1H), 6.82-6.76 (m, 3H), 6.08 (s, 2H), 5.43  
22 (brs, 1H), 5.39 (brs, 1H), 4.26 (q, *J* = 8.0 Hz, 2H), 3.67 (s, 2H), 1.33 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H}  
23 NMR (100 MHz, CDCl<sub>3</sub>) δ 172.8, 167.2, 147.50, 147.47, 135.5, 127.8, 124.4, 123.7, 116.8,  
24 109.5, 101.7, 60.7, 40.3, 14.3; HRMS (ESI-TOF) *m/z* Calcd for C<sub>14</sub>H<sub>15</sub>NNaO<sub>5</sub> [M + Na]<sup>+</sup>  
25 300.0842, found 300.0833.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **(E)-Ethyl 3-(2-(2-amino-2-oxoethyl)-4-methylphenyl)acrylate (4d):** Following **GP-A** the title  
38 compound was isolated as white solid (57 mg, 58% yield); R<sub>f</sub> ( 6:4 Hexanes/EtOAc) = 0.3; Mp  
39 142-144 °C; IR (ATR) 3386, 3194, 2976, 1711, 1651, 1312, 1175 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz,  
40 CDCl<sub>3</sub>) δ 7.87 (d, *J* = 16.0 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.15-7.11 (m, 2H), 6.35 (d, *J* = 16.0  
41 Hz, 1H), 5.49 (brs, 1H), 5.42 (brs, 1H), 4.25 (d, *J* = 6.8 Hz, 2H), 3.70 (s, 2H), 2.36 (s, 3H), 1.33  
42 (t, *J* = 6.8 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 172.7, 166.9, 140.95, 140.87, 134.1,  
43 132.1, 131.1, 129.1, 127.1, 119.9, 60.6, 40.5, 21.3, 14.3; HRMS (ESI-TOF) *m/z* Calcd for  
44 C<sub>14</sub>H<sub>17</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup> 270.1101, found 270.1108.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **(E)-3-(2-Carbamoylmethyl-4-fluoro-phenyl)-acrylic acid ethyl ester (4e):** Following GP-A  
4 the title compound was isolated as white solid (34 mg, 34% yield);  $R_f$  (6:4 Hexanes/EtOAc) =  
5 0.3; Mp 144-146 °C; IR (ATR) 3388, 3199, 1711, 1650, 1462, 1180, 657  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400  
6 MHz,  $\text{CDCl}_3$ )  $\delta$  7.69 (d,  $J = 16.0$  Hz, 1H), 7.33-7.32 (m, 1H), 7.13-7.08 (m, 2H), 6.58 (d,  $J =$   
7 16.0 Hz, 1H), 5.51 (brs, 2H), 4.25 (q,  $J = 8.0$  Hz, 2H), 3.72 (s, 2H), 1.33 (t,  $J = 8.0$  Hz, 3H);  
8  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 166.9, 163.08 and 160.56 ( $J_{\text{C-F}} = 252.0$  Hz), 136.53  
9 and 136.50 (d,  $J_{\text{C-F}} = 3.0$  Hz), 134.9, 130.86 and 130.77 (d,  $J_{\text{C-F}} = 9.0$  Hz), 127.0, 125.42 and  
10 125.29 (d,  $J_{\text{C-F}} = 13.0$  Hz), 122.43 and 122.31 (d,  $J_{\text{C-F}} = 12.0$  Hz), 115.72 and 115.49 (d,  $J_{\text{C-F}} =$   
11 23.0 Hz), 60.8, 40.6, 14.3; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{13}\text{H}_{14}\text{FNNaO}_3$  [ $\text{M} + \text{Na}$ ] $^+$   
12 274.0850, found 274.0850.

13  
14  
15 **(E)-Diethyl 2-(2-amino-2-oxoethyl)-5-methylstyrylphosphonate (4f):** Following GP-A the  
16 title compound was isolated as brownish sticky solid (52 mg, 42% yield);  $R_f$  (EtOAc) = 0.2; IR  
17 (ATR) 3352, 3199, 2986, 1668, 1198, 1021, 965;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.72 (t,  $J =$   
18 16.0 Hz, 1H), 7.38 (s, 1H), 7.18 (s, 2H), 6.19 (t,  $J = 16.0$  Hz, 1H), 5.79 (brs, 2H), 4.12 (m, 4H),  
19 3.65 (s, 2H), 2.35 (s, 3H), 1.33 (t,  $J = 8.0$  Hz, 6H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.9,  
20 145.8, 137.7, 134.22 and 134.00 (d,  $J = 22.0$  Hz), 131.4, 131.3, 131.2, 127.3, 117.18 and 115.23  
21 (d,  $J = 189.0$  Hz), 62.12, 62.07, 39.9, 21.0, 16.39, 16.32; HRMS (ESI-TOF)  $m/z$  Calcd for  
22  $\text{C}_{15}\text{H}_{22}\text{NNaPO}_4$  [ $\text{M} + \text{Na}$ ] $^+$  334.1179, found 334.1185.

23  
24  
25 **(E)-2-[2-(2-Benzenesulfonyl-vinyl)-4-methyl-phenyl]-acetamide (4g):** Following GP-A the  
26 title compound was isolated as brownish solid (86 mg, 68% yield);  $R_f$  (6:4 Hexanes/EtOAc) =  
27 0.25; Mp 172-174 °C; IR(ATR) 3429, 3302, 3187, 2926, 1662, 1298, 1139;  $^1\text{H}$  NMR (400 MHz,  
28 DMSO- $d_6$ )  $\delta$  7.93 (d,  $J = 8.0$  Hz, 2H), 7.88 (d,  $J = 16.0$  Hz, 1H), 7.74-7.70 (m, 1H), 7.67-7.63  
29 (m, 2H), 7.60 (s, 1H), 7.56 (brs, 1H), 7.45 (d,  $J = 16.0$  Hz, 1H), 7.20 (s, 2H), 7.00 (brs, 1H), 3.58  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(s, 2H), 2.26 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  171.7, 140.8, 140.0, 136.4, 134.0, 133.5, 131.5, 131.4, 131.3, 129.5, 128.9, 127.6, 127.2, 39.0, 20.4; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{17}\text{H}_{18}\text{NO}_3\text{S}$   $[\text{M} + \text{H}]^+$  316.1002, found 316.1025.

**(E)-2-[2-(2-Benzenesulfonyl-vinyl)-4-methoxy-phenyl]-acetamide (4h):** Following GP-A the title compound was isolated as brownish solid (77 mg, 61% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.25; Mp 153-155 °C; IR (ATR) 3394, 3177, 2922, 1654, 1402, 1143  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$  +  $\text{CDCl}_3$ )  $\delta$  7.93-7.91 (m, 2H), 7.86 (d,  $J$  = 15.2 Hz, 1H), 7.72-7.63 (m, 1H), 7.65-7.61 (m, 2H), 7.54 (s, 1H), 7.50 (s, 1H), 7.28 (d,  $J$  = 2.8 Hz, 1H), 7.22 (d,  $J$  = 8.4 Hz, 1H), 6.95-6.92 (m, 2H), 3.76 (s, 3H), 3.55 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (400 MHz, DMSO- $d_6$  +  $\text{CDCl}_3$ )  $\delta$  171.8, 158.2, 140.8, 139.9, 133.4, 132.43, 132.38, 129.4, 129.2, 128.5, 127.2, 117.4, 111.2, 55.3, 38.6; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{17}\text{H}_{18}\text{NO}_4\text{S}$   $[\text{M} + \text{H}]^+$  332.0951, found 332.0951.

**(E)-3-(2-Carbamoylmethyl-5-bromo-phenyl)-acrylic acid ethyl ester (4i):** Following GP-A the title compound was isolated as brownish solid (58 mg, 38% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3; Mp 158-160 °C; IR(ATR) 3458, 3301, 1682, 1292, 1143, 609  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.0 (s, 1H), 7.93 (d,  $J$  = 7.6 Hz, 2H), 7.82-7.73 (m, 2H), 7.69-7.65 (m, 3H), 7.62 (brs, 1H), 7.50-7.56 (m, 1H), 7.29 (d,  $J$  = 8.4 Hz, 1H), 7.07 (brs, 1H), 3.63 (s, 2H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  171.1, 140.5, 138.2, 136.1, 134.0, 133.6, 133.4, 133.2, 129.9, 129.5, 127.2, 120.3, 38.8; HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{16}\text{H}_{15}\text{BrNO}_3\text{S}$   $[\text{M} + \text{H}]^+$  379.9951, found 379.9956.

**(E)-3-(2-Carbamoylmethyl-5-chloro-phenyl)-acrylic acid ethyl ester (4j):** Following GP-A the title compound was isolated as brownish solid (44 mg, 33% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.3; Mp 199-201 °C; IR(ATR) 3427, 3190, 2921, 1661, 1304, 1143,  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,

1  
2  
3 DMSO-*d*<sub>6</sub>) δ 7.93 (d, *J* = 7.2 Hz, 2H), 7.87 (s, 1H), 7.82-7.72 (m, 2H), 7.68-7.64 (m, 3H), 7.61  
4 (brs, 1H), 7.45-7.43 (m, 1H), 7.34 (d, *J* = 8.4 Hz, 1H), 7.06 (brs, 1H), 3.64 (s, 2H); <sup>13</sup>C{<sup>1</sup>H}  
5 NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 171.6, 141.0, 138.8, 136.2, 134.1, 133.7, 132.4, 130.7, 130.4,  
6 130.0, 127.7, 127.1, 39.3; HRMS (ESI-TOF) *m/z* Calcd for C<sub>16</sub>H<sub>15</sub>ClNO<sub>3</sub>S [ M + H]<sup>+</sup> 336.0456,  
7 found 336.0445  
8  
9  
10  
11  
12  
13

14  
15 **(E)-2-(4-methyl-2-styrylphenyl)acetamide (4k):** Following **GP-A** the title compound was  
16 isolated as white solid (35 mg, 35% yield); *R*<sub>f</sub> (6:4 Hexanes/EtOAc) = 0.35; Mp 194-196 °C; IR  
17 (ATR) 3406, 3197, 2913, 1651, 1403 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 (d, *J* = 6.4 Hz,  
18 3H), 7.38 (t, *J* = 8.0 Hz, 2H), 7.31-7.26 (m, 2H), 7.17-7.11 (m, 2H), 7.06 (d, *J* = 16.0 Hz, 1H),  
19 5.68 (brs, 1H), 5.45 (brs, 1H), 3.72 (s, 2H), 2.41 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ  
20 173.6, 137.9, 137.0, 136.8, 131.5, 131.0, 129.6, 129.0, 128.7, 128.0, 126.9, 126.7, 125.0, 41.0,  
21 21.2; HRMS (ESI-TOF) *m/z* Calcd for C<sub>17</sub>H<sub>18</sub>NO [ M + H]<sup>+</sup> 252.1383, found 252.1376.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **(E)-2-(4-methoxy-2-styrylphenyl)acetamide (4l):** Following **GP-A** the title compound was  
33 isolated as white solid (38 mg, 36% yield); *R*<sub>f</sub> (6:4 Hexanes/EtOAc) = 0.35; Mp 151-153 °C; IR  
34 (ATR) 3386, 3196, 2924, 1651, 1500, 1400 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51 (d, *J* = 6.4  
35 Hz, 2H), 7.38-7.35 (m, 2H), 7.30 (s, 1H), 7.22-7.16 (m, 3H), 7.03 (d, *J* = 16.4 Hz, 1H), 6.85-6.33  
36 (m, 1H), 5.48 (brs, 1H), 5.39 (brs, 1H), 3.86 (s, 3H), 3.68 (s, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz,  
37 CDCl<sub>3</sub>) δ 173.7, 159.4, 138.2, 136.9, 132.2, 131.9, 128.8, 128.2, 126.8, 125.0, 113.9, 111.5, 55.4,  
38 40.6; HRMS (ESI-TOF) *m/z* Calcd for C<sub>17</sub>H<sub>18</sub>NO<sub>2</sub> [ M + H]<sup>+</sup> 268.1332, found 268.1333.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **(E)-3-[2-(1-Carbamoyl-ethyl)-phenyl]-acrylic acid ethyl ester (6a):** Following **GP-A** the title  
50 compound was isolated as white solid (62 mg, 64 % yield); *R*<sub>f</sub> (6:4 Hexanes/EtOAc) = 0.35; Mp  
51 105-107 °C; IR(ATR) 3361, 3175, 2926, 1705, 1658, 1452, 1191 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 CDCl<sub>3</sub>) δ 8.03 (d, *J* = 16.0 Hz, 1H), 7.55 (d, *J* = 8.0 Hz, 1H), 7.43-7.37 (m, 2H), 7.31-7.28 (m,  
4 1H), 6.35 (s, *J* = 8.0 Hz, 1H), 5.70 (brs, 1H), 5.50 (brs, 1H), 4.26 (q, *J* = 8.0 Hz, 2H), 3.99 (q, *J* =  
5 8.0 Hz, 1H), 1.51 (d, *J* = 8.0 Hz, 3H), 1.34 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  
6 δ 176.0, 166.7, 141.3, 140.4, 133.3, 130.6, 127.7, 127.3, 127.5, 60.8, 42.2, 18.5, 14.3; HRMS  
7 (ESI-TOF) *m/z* Calcd for C<sub>14</sub>H<sub>17</sub>NNaO<sub>3</sub> [ *M* + Na]<sup>+</sup> 270.1101, found 270.1095.  
8  
9

10  
11  
12 **(E)-2-[2-(2-Benzenesulfonyl-vinyl)-phenyl]-propionamide (6b):** Following GP-A the title  
13 compound was isolated as brownish solid (77 mg, 61% yield); *R<sub>f</sub>* ( 6:4 Hexanes/EtOAc) = 0.25;  
14  
15 Mp 149-151 °C; IR(ATR) 3428, 3310, 1666, 1299, 1140, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-  
16 *d*<sub>6</sub> + CDCl<sub>3</sub>) δ 8.04 (d, *J* = 16 Hz, 1H), 7.95-7.93 (m, 2H), 7.73-7.69 (m, 1H), 7.67-7.62 (m, 3H),  
17 7.46 (brs, 1H), 7.44-7.40 (m, 2H), 7.39-7.36 (m, 1H), 7.27-7.22 (m, 1H), 6.96 (brs, 1H), 3.98 (q,  
18 *J* = 8.0 Hz, 1H), 1.31 (d, *J* = 8.0 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (400 MHz, DMSO-*d*<sub>6</sub> + CDCl<sub>3</sub>) δ  
19 174.8, 142.3, 140.6, 139.4, 133.4, 130.8, 130.6, 129.45, 129.38, 127.5, 127.4, 127.1, 126.8, 41.3,  
20 19.0; HRMS (ESI-TOF) *m/z* Calcd for C<sub>17</sub>H<sub>18</sub>NO<sub>3</sub>S [ *M* + H]<sup>+</sup> 316.1002, found 316.0995.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33  
34 **(E)-Diethyl 2-(1-amino-1-oxopropan-2-yl)styrylphosphonate (6c):** Following GP-A the title  
35 compound was isolated as brownish sticky solid (56 mg, 45% yield); *R<sub>f</sub>* (EtOAc) = 0.2; IR(ATR)  
36 3350, 3197, 2980, 1671, 1222, 1018, 958; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95-7.85 (m, 1H),  
37 7.52-7.44 (m, 2H), 7.39-7.35 (m, 1H), 7.29-7.25 (m, 1H), 6.22-6.17 (m, 1H), 6.13 (brs, 1H), 5.92  
38 (brs, 1H), 4.15-4.06 (m, 4H), 4.01 (q, *J* = 8.0 Hz, 1H), 1.47 (d, *J* = 8.0 Hz, 3H), 1.35-1.31 (m,  
39 6H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 176.2, 146.10, 140.13, 133.81 and 133.59 (d, *J<sub>C-P</sub>* =  
40 22.0 Hz), 130.6, 127.7, 127.5, 126.5, 126.8, 118.01 and 116.12 (d, *J<sub>C-P</sub>* = 189.0 Hz), 62.08,  
41 62.03, 41.7, 18.6, 16.38, 16.32; HRMS (ESI-TOF) *m/z* Calcd for C<sub>15</sub>H<sub>22</sub>NNaPO<sub>4</sub> [ *M* + Na]<sup>+</sup>  
42 334.1179, found 334.1183.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **(E)-2-(2-Styryl-phenyl)-propionamide (6d):** Following GP-A the title compound was isolated  
4  
5 as white solid (42 mg, 42% yield);  $R_f$  (6:4 Hexanes/EtOAc) = 0.4; Mp 114-116 °C; IR(ATR)  
6  
7 3397, 3202, 2921, 1621, 1461, 762  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 (s, 1H), 7.52 (d,  $J$ =  
8  
9 6.4 Hz, 2H), 7.40-7.31 (m, 7H), 7.99 (d,  $J$  = 16.0 Hz, 1H), 5.49 (brs, 1H), 5.30 (brs, 1H), 3.97 (q,  
10  
11  $J$  = 7.2 Hz, 1H), 1.57 (d,  $J$  = 6.8 Hz, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  176.7, 138.6,  
12  
13 137.1, 136.6, 132.2, 128.8, 128.4, 128.0, 127.7, 127.5, 126.8, 126.7, 125.4, 43.1, 17.8; HRMS  
14  
15 (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{17}\text{H}_{18}\text{NO}$  [  $\text{M} + \text{H}$  ] $^+$  252.1383, found 252.1392.  
16  
17  
18  
19

20 **Procedure for preparative scale synthesis:** In an oven dried 100 mL round bottom flask  
21  
22 equipped with magnetic stir bar was sequentially added phenylacetamide (4.0 mmol, 1 equiv,  
23  
24 540 mg),  $\text{Pd}(\text{OAc})_2$  (10 mol %, 89.8 mg), benzoquinone ( 0.4 mmol, 1equiv, 432 mg). Then ethyl  
25  
26 acrylate (12 mmol, 3.0 equiv, 1.27 mL) followed by trifluoroacetic acid ( 40 mL) was added to  
27  
28 reaction mixture. The reaction mixture was purged with oxygen thrice. The flask was connected  
29  
30 to oxygen balloon through the condenser. The reaction mixture was placed in preheated oil bath  
31  
32 of 100 °C and vigorously stirred for 36 h. After cooling to room temperature, the solvent was  
33  
34 evaporated under reduced pressure and diluted with ethyl acetate followed by neutralization with  
35  
36 a saturated solution of sodium bicarbonate. After extraction with ethyl acetate (100 mL x 3)  
37  
38 organic layer was washed with brine solution and filtered through a short pad of celite and dried  
39  
40 over sodium sulfate and concentrated under *vacuum*. The crude mixture was purified by silica gel  
41  
42 column chromatography and ethyl acetate/hexanes as eluent to give **3a** 57% (530 mg) of  
43  
44 alkenylated derivative.  
45  
46  
47  
48  
49

50  
51 **Synthesis of (E)-ethyl 3-(2-(Cyanomethyl)phenyl)acrylate (7a)** By following a reported  
52  
53 procedure<sup>16a</sup> **3a** (0.2 mmol, 46 mg) in a mixture of  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (1:1) was treated with  $\text{PdCl}_2$  (10  
54  
55 mol%, 3.5 mg) at 50 °C for 12 h. After completion, reaction mixture was quenched with water  
56  
57  
58  
59  
60

1  
2  
3 and extracted with ethyl acetate (10 mL x 3). Solvent was removed in *vacuum* and crude product  
4  
5 was purified by column chromatography.  
6  
7

8 **(E)-3-(2-Cyanomethyl-phenyl)-acrylic acid ethyl ester (7a):** white solid (35 mg, 82% yield);  
9  
10  $R_f$  (1:10 Hexanes/EtOAc) = 0.5; Mp 69-71 °C; IR(ATR) 2941, 2220, 1703, 1632, 3112, 1175,  
11  
12 765  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.81 (d,  $J$  = 16.0 Hz, 1H), 7.59 (d,  $J$  = 8.0 Hz, 1H), 7.51  
13  
14 (d,  $J$  = 8.0 Hz, 1H), 7.44-7.36 (m, 2H), 6.39 (d,  $J$  = 16.0 Hz, 1H), 4.28 (q,  $J$  = 7.2 Hz, 2H), 3.86  
15  
16 (s, 2H), 1.34 (t,  $J$  = 8.0 Hz, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  166.3, 139.7, 133.3, 130.6,  
17  
18 129.3, 128.90, 128.86, 127.4, 122.1, 117.1, 60.9, 21.8, 14.3; HRMS (ESI-TOF)  $m/z$  Calcd for  
19  
20  $\text{C}_{13}\text{H}_{13}\text{NNaO}_2$   $[\text{M} + \text{Na}]^+$  238.0838, found 238.0851.  
21  
22  
23  
24

25 **3-[2-(Methoxycarbonylamino-methyl)-phenyl]-acrylic acid methyl ester (7b)** By following a  
26  
27 reported procedure<sup>16b</sup> a mixture of oxone (0.4 mmol, 122.8 mg) and iodobenzene (0.2 mmol, 33  
28  
29  $\mu\text{L}$ ) was prepared in methanol (2.0 mL), 3a (0.2 mmol, 46 mg) was added in reaction mixture  
30  
31 and stir for 24 h at 100 °C. After completion reaction mixture solvent was evaporated in *vacuo*  
32  
33 and extracted with ethyl acetate (10 mL x 3). Solvent was removed in *vacuum* and crude product  
34  
35 was purified by column chromatography.  
36  
37  
38  
39

40 **3-[2-(Methoxycarbonylamino-methyl)-phenyl]-acrylic acid methyl ester (7b):** colorless  
41  
42 liquid  $R_f$  (10:1 Hexanes/EtOAc) = 0.4;(35 mg, 70% yield); IR (ATR) 2952, 1714, 1634, 1434,  
43  
44 1318, 1167, 765  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.95 (d,  $J$  = 16.0 Hz, 1H), 7.59 (d,  $J$  = 8.0  
45  
46 Hz, 1H), 7.34-7.28 (m, 3H), 6.37 (d,  $J$  = 16.0 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 2H). 3.69 (s, 3H);  
47  
48  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.4, 167.2, 141.9, 134.0, 133.6, 131.1, 130.2, 127.9,  
49  
50 126.9, 120.1, 52.2, 51.8, 38.6. HRMS (ESI-TOF)  $m/z$  Calcd for  $\text{C}_{13}\text{H}_{14}\text{NaO}_4$   $[\text{M} + \text{Na}]^+$  257.0784,  
51  
52 found 257.0797.  
53  
54  
55  
56  
57  
58  
59  
60

**3-(2-Carboxymethyl-phenyl)-acrylic acid (7c)** By following a reported procedure<sup>16c</sup> a mixture of **3a** (0.2 mmol, 46 mg) was prepared in 20% (v/v) H<sub>2</sub>SO<sub>4</sub> (2.5 mL) and heated at 100 °C for 6 h. After completion of reaction, mixture was cooled to room temperature and diluted with water then extracted with ethylacetate (15 mL x 3). Organic layer was dried in *vacuum*. Recrystallization with dichloromethane and hexane produced white solid.

**3-(2-Carboxymethyl-phenyl)-acrylic acid (7c)** white solid (30 mg, 73 %), Mp 130-132 °C IR(ATR) 2925 (br), 1682, 1619, 1220, 974; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 7.78-7.74 (m, 2H), 7.38-7.29 (m, 3H), 6.43 (d, *J* = 16.0 Hz, 2H), 3.75 (s, 2H); <sup>13</sup>C {<sup>1</sup>H} NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 172.3, 167.5, 141.1, 134.8, 133.6, 131.5, 130.0, 127.6, 126.7, 38.5; HRMS (ESI-TOF) *m/z* Calcd for C<sub>11</sub>H<sub>10</sub>NaO<sub>4</sub> [M + Na]<sup>+</sup> 229.0471, found 229.0501.

**(E)-ethyl 3-(2-(2-(benzylamino)-2-oxoethyl)phenyl)acrylate (9)**: Following **GP-A** the title compound was isolated as white solid (16 mg, 25% yield); R<sub>f</sub> (7:3 Hexanes/EtOAc) = 0.4; Mp 105-107 °C; IR(ATR) 3285, 2924, 1708, 1640, 1542, 1316, cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (d, *J* = 16.0 Hz, 1H), 7.59 (m, 1H), 7.35-7.26 (m, 6H), 7.26-7.16 (m, 2H), 6.35 (d, *J* = 16.0 Hz, 1H), 5.70 (brs, 1H), 4.40(d, *J* = 4.0 Hz, 2H), 4.26 (q, *J* = 8/0 Hz, 2H), 3.77 (s, 2H), 1.33 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C {<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 168.9, 166.5, 140.9, 137.0, 134.1, 131.4, 130.5, 128.6, 128.2, 127.5, 127.4, 127.2, 121.1, 60.7, 43.6, 41.2; HRMS (ESI-TOF) *m/z* Calcd for C<sub>20</sub>H<sub>21</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup> 346.1414, found 346.1459.

**Procedure for intermolecular competition experiment between 1d and 1e**: A suspension of Pd(OAc)<sub>2</sub> (10 mol %, 3.5 mg) BQ ( 1 equiv, 16.2 mg) ethyl acrylate ( 3 equiv, 48 μL), **1d** (0.15 mmol, 22.3 mg, 1 equiv) and **1e** (0.15 mmol, 23 mg, 1 equiv) was stirred in TFA (2.0 mL) under oxygen for 36 h at 100 °C. After cooling to room temperature, solvent was evaporated in

1  
2  
3 vacuum. Reaction mixture was dilute with ethyl acetate, followed by neutralization with aqueous  
4 solution of sodium bicarbonate. After extraction with ethyl acetate organic layer was washed  
5 with brine solution and filtered through short pad of celite and dried over sodium sulphate.  
6  
7 Combined organic layer was concentrated under vacuum. The crude mixture was purified by  
8 column chromatography using ethyl acetate/hexanes as eluent. Compounds **4d** and **4e** were  
9  
10 obtained in 48% and 13% respectively.  
11  
12  
13  
14  
15  
16  
17

**Procedure for intermolecular competition experiment between 2a and 2g:** A suspension of  
18 **1a** (0.2 mmol, 27 mg), Pd(OAc)<sub>2</sub> (10 mol%, 4.5 mg) BQ (1 equiv, 21.6 mg), ethyl acrylate (3  
19 equiv, 64 μL) and phenyl vinyl sulfone (3.0 equiv, 100 mg) was stirred in TFA (3.0 mL) under  
20 oxygen for 36 h at 100°C. After cooling to room temperature, the solvent was evaporated in  
21 vacuum. The reaction mixture was diluted with ethyl acetate and followed by neutralization with  
22 anaqueous solution of sodium bicarbonate. After extraction with ethyl acetate organic layer was  
23 washed with brine solution and passed through a short pad of celite and dried over sodium  
24 sulfate. Combined organic layer was concentrated under vacuum. The crude mixture was  
25 purified by column chromatography using ethyl acetate/hexanes as eluent. Compounds **3a** and **3g**  
26 were obtained in 43% and 48% respectively.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

**Kinetic isotope effect experiment: Procedure for intermolecular competitive experiment**  
41 **between 1a and 1a-d<sub>5</sub>:** A mixture of **1a** (0.15 mmol) and **1a-d<sub>5</sub>** (0.15 mmol), Pd(OAc)<sub>2</sub> (10 mol  
42 %, 6.7 mg), BQ (1 equiv, 32.4 mg), (3 equiv, 48 μL) was stirred in TFA (3.0 mL) under oxygen  
43 for 3 h at 100 °C. After cooling to room temperature, the solvent was evaporated in vacuum. The  
44 reaction mixture was diluted with ethyl acetate, followed by neutralization with anaqueous  
45 solution of sodium bicarbonate. After extraction with ethyl acetate organic layer was washed  
46 with brine solution and filtered through a short pad of celite and dried over sodium sulfate.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Combined organic layer was concentrated under vacuum. The crude mixture was purified by  
4 column chromatography using ethyl acetate/hexanes as eluent to give **3a/3a-d<sub>4</sub>** (15 mg, 24%).  
5  
6  
7 The ratio of **3a** and **3a-d<sub>4</sub>** was determined by <sup>1</sup>H NMR. The kinetic isotope effect of the reaction  
8  
9 was determined to be  $k_H/k_D = 4.0$  (see SI for details).  
10  
11  
12

## 13 ASSOCIATED CONTENT

### 14 15 16 Supporting Information

17  
18  
19 The Supporting Information is available free of charge on the ACS Publications website.  
20  
21

22 Additional screening data, mechanistic experimental details, <sup>1</sup>H and <sup>13</sup>C NMR spectra of all new  
23 products  
24  
25  
26

## 27 28 AUTHOR INFORMATION

### 29 30 31 Corresponding Author

32  
33  
34 \*E-mail: [amitkt@iitp.ac.in](mailto:amitkt@iitp.ac.in) or [amitktiitk@gmail.com](mailto:amitktiitk@gmail.com)  
35  
36

### 37 38 Notes

39  
40 The authors declare no competing financial interest.  
41  
42

## 43 44 ACKNOWLEDGMENTS

45  
46 Authors gratefully acknowledge Indian Institute of Technology (IIT) Patna and CSIR, New  
47 Delhi (02(0229)/15/EMR-II), for financial support. Y. Jaiswal and Y. Kumar thank IIT Patna for  
48 an Institute Research Fellowship. The authors also acknowledge SAIF-Punjab University for  
49 providing NMR facilities and SAIF-IIT Patna for HRMS facilities.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- (1) (a) Cheng, D.; Liu, J.; Han, D.; Zhang, G.; Gao, W.; Hsieh, M. H.; Ng, N.; Kasibhatla, S.; Tompkins, C.; Li, J.; Steffy, A.; Sun, F.; Li, C.; Seidel, H. M.; Harris, J. L.; Pan, S. *ACS Med. Chem. Lett.* **2016**, *7*, 676. (b) Souers, A. J.; Gao, J.; Brune, M.; Bush, E.; Wodka, D.; Vasudevan, A.; Judd, A. S.; Mulhern, M.; Brodjian, S.; Dayton, B.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. *J. Med. Chem.* **2005**, *48*, 1318. (c) Wang, Y.; Cai, W.; Cheng, Y.; Yang, T.; Liu, Q.; Zhang, G.; Meng, Q.; Han, F.; Huang, Y.; Zhou, L.; Xiang, Z.; Zhao, Y.-G.; Xu, Y.; Cheng, Z.; Lu, S.; Wu, Q.; Xiang, J.-N.; Elliott, J. D.; Leung, S.; Ren, F.; Lin, X., *ACS Med. Chem. Lett.* **2015**, *6*, 787. (d) Zheng, X.; Wang, L.; Wang, B.; Miao, K.; Xiang, K.; Feng, S.; Gao, L.; Shen, H. C.; Yun, H., *ACS Med. Chem. Lett.* **2016**, *7*, 558. (e) Pattabiraman, V. R.; Bode, J. W. *Nature* **2011**, *480*, 471.
- (2). For selected reviews on amide as directing group (a) Rouquet, G.; Chatani, N. *Angew. Chem., Int. Ed.* **2013**, *52*, 11726. (b) Zhu, R.-Y.; Farmer, M. E.; Chen, Y.-Q.; Yu, J.-Q. *Angew. Chem., Int. Ed.* **2016**, *55*, 10578. (c) Das, R.; Kumar, G. S.; Kapur, M. *Eur. J. Org. Chem.* **2017**, 5439.
- (3) (a) Yeung, C. S.; Zhao, X.; Borduas, N.; Dong, V. M. *Chem. Sci.* **2010**, *1*, 331. (b) Zhao, S.; Yuan, J.; Li, Y.-C.; Shi, B.-F. *Chem. Commun.* **2015**, *51*, 12823. (c) Lu, Y.; Wang, H.-W.; Spangler, J. E.; Chen, K.; Cui, P.-P.; Zhao, Y.; Sun, W.-Y.; Yu, J.-Q. *Chem. Sci.* **2015**, *6*, 1923. (d) Manoharan, R.; Sivakumar, G.; Jeganmohan, M. *Chem. Commun.* **2016**, *52*, 10533. (e) Keshri, P.; Bettadapur, K. R.; Lanke, V.; Prabhu, K. R. *J. Org. Chem.* **2016**, *81*, 6056. (f) Park, J.; Han, S.; Jeon, M.; Mishra, N. K.; Lee, S.-Y.; Lee, J. S.; Kwak, J. H.; Um, S. H.; Kim, I. S. *J. Org. Chem.* **2016**, *81*, 11353. (g) Ye, X.; Zhang, Y.; He, Y.; Shi, X. *Tetrahedron* **2016**, *72*, 2756.

1  
2  
3 (h) Wang, H.-W.; Lu, Y.; Zhang, B.; He, J.; Xu, H.-J.; Kang, Y.-S.; Sun, W.-Y.; Yu, J.-Q.  
4  
5 *Angew. Chem. Int. Ed.* **2017**, *56*, 7449.  
6  
7

8  
9 (4) (a) Besset, T.; Kuhl, N.; Patureau, F. W.; Glorius, F. *Chem. Eur. J.* **2011**, *17*, 7167. (b) Wang,  
10  
11 L.; Ackermann, L., *Chem. Commun.* **2014**, *50*, 1083. (c) Zhao, Y.; Snieckus, V. *J. Am. Chem.*  
12  
13 *Soc.* **2014**, *136*, 11224. (d) Guo, L.; Chen, Y.; Zhang, R.; Peng, Q.; Xu, L.; Pan, X. *Chem. Asian*  
14  
15 *J.* **2017**, *12*, 289. (e) Li, F.; Yu, C.; Zhang, J.; Zhong, G. *Org. Biomol. Chem.* **2017**, *15*, 1236.  
16

17  
18 (5) (a) Satoshi, M.; Nobuyoshi, U.; Koji, H.; Tetsuya, S.; Masahiro, M. *Chem. Lett.* **2010**, *39*,  
19  
20 744. (b) Song, G.; Chen, D.; Pan, C.-L.; Crabtree, R. H.; Li, X. *J. Org. Chem.* **2010**, *75*, 7487. (c)  
21  
22 Patureau, F. W.; Besset, T.; Glorius, F. *Angew. Chem. Int. Ed.* **2011**, *50*, 1064. (d) Li, D.-D.;  
23  
24 Yuan, T.-T.; Wang, G.-W. *J. Org. Chem.* **2012**, *77*, 3341. (e) Laha, J. K.; Shah, P. U.; Jethava, K.  
25  
26 P., *Chem. Commun.* **2013**, *49*, 7623.  
27

28  
29 (6) For selected reviews see (a) Le Bras, J.; Muzart, J. *Chem. Rev.* **2011**, *111*, 1170. (b) Wu, Y.;  
30  
31 Wang, J.; Mao, F.; Kwong, F. Y. *Chem. Asian J.* **2014**, *9*, 26. (c) Yeung, C. S.; Dong, V. M.  
32  
33 *Chem. Rev.* **2011**, *111*, 1215. (d) Zhou, L.; Lu, W. *Chem. Eur. J.* **2014**, *20*, 634. (e) Liu, C.;  
34  
35 Yuan, J.; Gao, M.; Tang, S.; Li, W.; Shi, R.; Lei, A. *Chem. Rev.* **2015**, *115*, 12138. (f) Varun, B.  
36  
37 V.; Dhineshkumar, J.; Bettadapur, K. R.; Siddaraju, Y.; Alagiri, K.; Prabhu, K. R. *Tetrahedron*  
38  
39 *Lett.* **2017**, *58*, 803.  
40  
41

42  
43 (7) (a) Hao, X.-Q.; Chen, L.-J.; Ren, B.; Li, L.-Y.; Yang, X.-Y.; Gong, J.-F.; Niu, J.-L.; Song,  
44  
45 M.-P. *Org. Lett.* **2014**, *16*, 1104. (b) Miura, W.; Hirano, K.; Miura, M. *Org. Lett.* **2015**, *17*, 4034  
46  
47 (c) Rao, W.-H.; Shi, B.-F. *Org. Lett.* **2015**, *17*, 2784. (d) Sun, S.-Z.; Shang, M.; Wang, H.-L.;  
48  
49 Lin, H.-X.; Dai, H.-X.; Yu, J.-Q., *J. Org. Chem.* **2015**, *80*, 8843. (e) Zhang, L.-B.; Hao, X.-Q.;  
50  
51 Zhang, S.-K.; Liu, Z.-J.; Zheng, X.-X.; Gong, J.-F.; Niu, J.-L.; Song, M.-P. *Angew. Chem., Int.*  
52  
53 *Ed.* **2015**, *54*, 272.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (8) (a) Deb, A.; Bag, S.; Kancherla, R.; Maiti, D. *J. Am. Chem. Soc.* **2014**, *136*, 13602. (b) Li, G.;  
4  
5 Wan, L.; Zhang, G.; Leow, D.; Spangler, J.; Yu, J.-Q. *J. Am. Chem. Soc.* **2015**, *137*, 4391.  
6  
7 (9) Jaiswal, Y.; Kumar, Y.; Thakur, R.; Pal, J.; Subramanian, R.; Kumar, A. *J. Org. Chem.*  
8  
9 **2016**, *81*, 12499.  
10  
11 (10) (a) Kumar, Y.; Jaiswal, Y.; Kumar, A. *J. Org. Chem.* **2016**, *81*, 12247. (b) Kumar, Y.;  
12  
13 Shaw, M.; Thakur, R.; Kumar, A. *J. Org. Chem.* **2016**, *81*, 6617. (c) Kumar, Y.; Jaiswal, Y.;  
14  
15 Shaw, M.; Kumar, A. *Chem. Select* **2017**, *2*, 6143.  
16  
17 (11) (a) Laha, J. K.; Kaur Hunjan, M.; Bhimpuria, R. A.; Kathuria, D.; Bharatam, P. V. *J. Org.*  
18  
19 *Chem.* **2017**, *82*, 7346. (b) Lee, J. M.; Ahn, D.-S.; Jung, D. Y.; Lee, J.; Do, Y.; Kim, S. K.;  
20  
21 Chang, S. *J. Am. Chem. Soc.* **2006**, *128*, 12954.  
22  
23 (12) Simmons, E. M.; Hartwig, J. F. *Angew. Chem., Int. Ed.* **2012**, *51*, 3066.  
24  
25 (13) (a) Engle, K. M.; Wang, D.-H.; Yu, J.-Q. *J. Am. Chem. Soc.* **2010**, *132*, 14137. (b) Park, J.;  
26  
27 Kim, M.; Sharma, S.; Park, E.; Kim, A.; Lee, S. H.; Kwak, J. H.; Jung, Y. H.; Kim, I. S. *Chem.*  
28  
29 *Commun.* **2013**, *49*, 1654. (c) Hu, J.; Guan, M.; Han, J.; Huang, Z.-B.; Shi, D.-Q.; Zhao, Y. *J.*  
30  
31 *Org. Chem.* **2015**, *80*, 7896. (d) Deb, A.; Hazra, A.; Peng, Q.; Paton, R. S.; Maiti, D. *J.*  
32  
33 *Am. Chem. Soc.* **2017**, *139*, 763.  
34  
35 (14) (a) Yoo, E. J.; Ma, S.; Mei, T.-S.; Chan, K. S. L.; Yu, J.-Q. *J. Am. Chem. Soc.* **2011**, *133*,  
36  
37 7652. (b) Yu, M.; Xie, Y.; Xie, C.; Zhang, Y. *Org. Lett.* **2012**, *14*, 2164. (c) Wang, Y.; Zhou, K.;  
38  
39 Lan, Q.; Wang, X.-S. *Org. Biomol. Chem.* **2015**, *13*, 353.  
40  
41 (15) (a) Moorthy, J. N.; Singhal, N. *J. Org. Chem.* **2005**, *70*, 1926. (b) Veisi, H.; Maleki, B.;  
42  
43 Hamelian, M.; Ashrafi, S. S. *RSC Adv.* **2015**, *5*, 6365.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (16) (a) Maffioli, S. I.; Marzorati, E.; Marazzi, A. *Org. Lett.* **2005**, *7*, 5237 (b) Zagulyaeva, A.  
4  
5 A.; Banek, C. T.; Yusubov, M. S.; Zhdankin, V. V. *Org. Lett.* **2010**, *12*, 4644. (c) Stadler, A.;  
6  
7 Pichler, S.; Horeis, G.; Kappe, C. O. *Tetrahedron* **2002**, *58*, 3177.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60